Treatment with Bay 60 reduced PE contractility both at 0.3 mg/kg and 3 mg/kg (Figures 2B,C, P < 0.01), suggesting that both doses, which showed similar plasma exposure of the sGC activator, protected against diabetes-mediated vascular dysfunction. The gene discussed is SGCB; the disease is diabetes mellitus.